Leukocyte Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major leukocyte disorders markets reached a value of US$ 57.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 89.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.18% during 2024-2034.
The leukocyte disorders market has been comprehensively analyzed in IMARC's new report titled "Leukocyte Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leukocyte disorders, also known as leukocytosis and leukopenia, encompass a range of conditions characterized by abnormal levels of white blood cells (leukocytes) in the bloodstream. Leukocytes play an important role in the immune system, defending the body against infections and diseases. Leukocytosis refers to an increased white blood cell count, often indicative of an underlying infection, inflammatory response, or bone marrow disorder. Symptoms may include fever, fatigue, enlarged lymph nodes, and potential complications related to the underlying cause. Leukopenia, on the other hand, signifies a lower-than-normal white blood cell count, potentially weakening the immune system and leaving the body susceptible to infections. Symptoms of leukopenia can include recurrent infections, slow wound healing, and general malaise. The diagnosis of leukocyte disorders involves a comprehensive assessment of the patient's clinical history, physical examination, and blood workups, such as a complete blood count (CBC), to quantify the different types of white blood cells.
The increasing prevalence of bone marrow dysfunction, which can disrupt the normal production and function of white blood cells, is primarily driving the leukocyte disorders market. In addition to this, the inflating utilization of advanced therapeutic approaches, including targeted therapies and immunomodulatory drugs, is also creating a positive outlook for the market. These treatments help to restore the balance of white blood cell counts, ensuring a more effective immune response and ultimately ameliorating the symptoms associated with various leukocyte disorders. Moreover, the widespread adoption of supportive care strategies, such as prophylactic antibiotics and growth factors, to enhance the quality of life for patients is further bolstering the market growth. Apart from this, the rising usage of innovative diagnostic methods, including flow cytometry and molecular genetic tests, that facilitate early and accurate diagnosis of the disease is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene-editing technologies like CRISPR, since they can directly modify or correct the genes responsible for the underlying conditions, is also augmenting the market growth. Furthermore, the escalating application of bone marrow and stem cell transplantation techniques aimed at replenishing malfunctioning white blood cells with healthy ones is expected to drive the leukocyte disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the leukocyte disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for leukocyte disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leukocyte disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the leukocyte disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the leukocyte disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current leukocyte disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the leukocyte disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the leukocyte disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the leukocyte disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of leukocyte disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukocyte disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukocyte disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukocyte disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with leukocyte disorders across the seven major markets?
What is the size of the leukocyte disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of leukocyte disorders?
What will be the growth rate of patients across the seven major markets?
Leukocyte Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for leukocyte disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leukocyte disorders market?
What are the key regulatory events related to the leukocyte disorders market?
What is the structure of clinical trial landscape by status related to the leukocyte disorders market?
What is the structure of clinical trial landscape by phase related to the leukocyte disorders market?
What is the structure of clinical trial landscape by route of administration related to the leukocyte disorders market?
The leukocyte disorders market has been comprehensively analyzed in IMARC's new report titled "Leukocyte Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leukocyte disorders, also known as leukocytosis and leukopenia, encompass a range of conditions characterized by abnormal levels of white blood cells (leukocytes) in the bloodstream. Leukocytes play an important role in the immune system, defending the body against infections and diseases. Leukocytosis refers to an increased white blood cell count, often indicative of an underlying infection, inflammatory response, or bone marrow disorder. Symptoms may include fever, fatigue, enlarged lymph nodes, and potential complications related to the underlying cause. Leukopenia, on the other hand, signifies a lower-than-normal white blood cell count, potentially weakening the immune system and leaving the body susceptible to infections. Symptoms of leukopenia can include recurrent infections, slow wound healing, and general malaise. The diagnosis of leukocyte disorders involves a comprehensive assessment of the patient's clinical history, physical examination, and blood workups, such as a complete blood count (CBC), to quantify the different types of white blood cells.
The increasing prevalence of bone marrow dysfunction, which can disrupt the normal production and function of white blood cells, is primarily driving the leukocyte disorders market. In addition to this, the inflating utilization of advanced therapeutic approaches, including targeted therapies and immunomodulatory drugs, is also creating a positive outlook for the market. These treatments help to restore the balance of white blood cell counts, ensuring a more effective immune response and ultimately ameliorating the symptoms associated with various leukocyte disorders. Moreover, the widespread adoption of supportive care strategies, such as prophylactic antibiotics and growth factors, to enhance the quality of life for patients is further bolstering the market growth. Apart from this, the rising usage of innovative diagnostic methods, including flow cytometry and molecular genetic tests, that facilitate early and accurate diagnosis of the disease is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene-editing technologies like CRISPR, since they can directly modify or correct the genes responsible for the underlying conditions, is also augmenting the market growth. Furthermore, the escalating application of bone marrow and stem cell transplantation techniques aimed at replenishing malfunctioning white blood cells with healthy ones is expected to drive the leukocyte disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the leukocyte disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for leukocyte disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leukocyte disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the leukocyte disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the leukocyte disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current leukocyte disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the leukocyte disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the leukocyte disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the leukocyte disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of leukocyte disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukocyte disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukocyte disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukocyte disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with leukocyte disorders across the seven major markets?
What is the size of the leukocyte disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of leukocyte disorders?
What will be the growth rate of patients across the seven major markets?
Leukocyte Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for leukocyte disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leukocyte disorders market?
What are the key regulatory events related to the leukocyte disorders market?
What is the structure of clinical trial landscape by status related to the leukocyte disorders market?
What is the structure of clinical trial landscape by phase related to the leukocyte disorders market?
What is the structure of clinical trial landscape by route of administration related to the leukocyte disorders market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LEUKOCYTE DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LEUKOCYTE DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LEUKOCYTE DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 LEUKOCYTE DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LEUKOCYTE DISORDERS - UNMET NEEDS
10 LEUKOCYTE DISORDERS - KEY ENDPOINTS OF TREATMENT
11 LEUKOCYTE DISORDERS - MARKETED PRODUCTS
11.1 List of Leukocyte Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) - Amgen/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LEUKOCYTE DISORDERS - PIPELINE DRUGS
12.1 List of Leukocyte Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Mavorixafor - X4 Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. LEUKOCYTE DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LEUKOCYTE DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LEUKOCYTE DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Leukocyte Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Leukocyte Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Leukocyte Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Leukocyte Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Leukocyte Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Leukocyte Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Leukocyte Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Leukocyte Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Leukocyte Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Leukocyte Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Leukocyte Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Leukocyte Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Leukocyte Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Leukocyte Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Leukocyte Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Leukocyte Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Leukocyte Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Leukocyte Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Leukocyte Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Leukocyte Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Leukocyte Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Leukocyte Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Leukocyte Disorders - Access and Reimbursement Overview
16 LEUKOCYTE DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LEUKOCYTE DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LEUKOCYTE DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LEUKOCYTE DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LEUKOCYTE DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LEUKOCYTE DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 LEUKOCYTE DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LEUKOCYTE DISORDERS - UNMET NEEDS
10 LEUKOCYTE DISORDERS - KEY ENDPOINTS OF TREATMENT
11 LEUKOCYTE DISORDERS - MARKETED PRODUCTS
11.1 List of Leukocyte Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) - Amgen/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LEUKOCYTE DISORDERS - PIPELINE DRUGS
12.1 List of Leukocyte Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Mavorixafor - X4 Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. LEUKOCYTE DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LEUKOCYTE DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LEUKOCYTE DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Leukocyte Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Leukocyte Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Leukocyte Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Leukocyte Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Leukocyte Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Leukocyte Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Leukocyte Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Leukocyte Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Leukocyte Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Leukocyte Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Leukocyte Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Leukocyte Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Leukocyte Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Leukocyte Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Leukocyte Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Leukocyte Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Leukocyte Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Leukocyte Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Leukocyte Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Leukocyte Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Leukocyte Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Leukocyte Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Leukocyte Disorders - Access and Reimbursement Overview
16 LEUKOCYTE DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LEUKOCYTE DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LEUKOCYTE DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
